Investors Purchase Large Volume of Call Options on SIGA Technologies (NASDAQ:SIGA)

SIGA Technologies, Inc. (NASDAQ:SIGA) was the target of unusually large options trading on Wednesday. Stock traders acquired 1,200 call options on the company. This is an increase of 1,438% compared to the typical daily volume of 78 call options.

SIGA Technologies Stock Up 1.0 %

Shares of SIGA opened at $6.00 on Thursday. The stock’s 50-day moving average price is $6.71 and its 200 day moving average price is $7.69. SIGA Technologies has a 12-month low of $4.26 and a 12-month high of $12.83. The firm has a market capitalization of $428.43 million, a price-to-earnings ratio of 5.00 and a beta of 0.89.

SIGA Technologies (NASDAQ:SIGA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.02 earnings per share (EPS) for the quarter. The business had revenue of $10.01 million for the quarter. SIGA Technologies had a return on equity of 49.06% and a net margin of 49.33%. Equities research analysts expect that SIGA Technologies will post 1.04 EPS for the current year.

Hedge Funds Weigh In On SIGA Technologies

Hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC acquired a new stake in shares of SIGA Technologies during the 3rd quarter valued at about $30,000. DekaBank Deutsche Girozentrale bought a new position in SIGA Technologies during the second quarter worth about $40,000. EP Wealth Advisors LLC acquired a new stake in SIGA Technologies during the third quarter valued at approximately $82,000. XTX Topco Ltd acquired a new stake in SIGA Technologies during the third quarter valued at approximately $85,000. Finally, AQR Capital Management LLC bought a new stake in shares of SIGA Technologies in the 2nd quarter valued at approximately $99,000. Institutional investors and hedge funds own 55.40% of the company’s stock.

About SIGA Technologies

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.